Form 4: Silexion CEO Ilan Hadar Reports Share Grant Amid Reverse Splits
Insider Transaction Report
Silexion Therapeutics Corp's Chairman and CEO, Ilan Hadar, reported the acquisition of 64,350 ordinary shares through a restricted share unit grant, following two significant reverse stock splits.
Summary
- Ilan Hadar, Chairman and CEO of Silexion Therapeutics Corp (SLXN), reported changes in beneficial ownership via a Form 4 filing.
- He acquired 64,350 ordinary shares on February 20, 2026, through a grant of fully vested Restricted Share Units (RSUs).
- These RSUs were immediately settled for underlying ordinary shares, a transaction approved by the Issuer's board of directors.
- The reported share numbers reflect adjustments due to two reverse share splits: a 1-for-9 split on November 29, 2024, and a 1-for-15 split on July 29, 2025.
- Following this transaction, Ilan Hadar beneficially owns 65,471 ordinary shares directly.
- He also holds stock options to purchase 956 ordinary shares with an exercise price of $907.71, which have also been adjusted for the reverse splits.
- A Power of Attorney was granted by Ilan Hadar to Mirit Horenshtein Hadar, the company's Chief Financial Officer, on August 15, 2024, to facilitate the filing of Section 16 reports on his behalf.
Sentiment
Score: 3
Explanation: StockSavvy.ai views this filing with a low sentiment score primarily due to the disclosure of two significant reverse stock splits, which typically signal severe underlying financial or operational challenges despite the positive aspect of an insider share grant.
Positives
- The grant of 64,350 fully vested restricted share units to the Chairman and CEO, immediately settled for ordinary shares, indicates management compensation and aligns executive interests with shareholder value.
- The RSU grant was approved by the Issuer's board of directors, suggesting adherence to corporate governance procedures for executive compensation.
Negatives
- The disclosure of two significant reverse share splits (1-for-9 on November 29, 2024, and 1-for-15 on July 29, 2025) indicates a substantial loss of market capitalization and shareholder value prior to the reported transaction.
Risks
- The history of multiple reverse share splits within a short timeframe suggests ongoing financial instability and a high risk of continued share price depreciation.
- Companies undertaking such drastic measures often face challenges in maintaining exchange listing requirements, posing a potential delisting risk.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that insider share grants, while common for executive compensation, should be viewed in the context of the company's broader performance. The two recent reverse stock splits suggest significant challenges for Silexion Therapeutics Corp, potentially indicating a need to maintain listing requirements or address a severely depressed share price, which is a concerning trend in the biotech sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Delegation of Authority | Ilan Hadar granted a Power of Attorney to Mirit Horenshtein Hadar (CFO) to prepare and file Forms 3, 4, and 5 on his behalf, effective August 15, 2024. This streamlines compliance with Section 16(a) of the Exchange Act. | August 15, 2024 | Enhances efficiency and ensures timely compliance with SEC reporting requirements for insider transactions. |
Related Party Transactions
- Grant of 64,350 fully vested restricted share units (RSUs) to Ilan Hadar, Chairman and CEO, which were immediately settled for ordinary shares. This transaction was approved by the Issuer's board of directors.
Stakeholder Impact
- Shareholders: The grant of shares to the CEO aligns management's interests with shareholders. However, the underlying reverse stock splits indicate significant dilution or value destruction for existing shareholders.
- Management: Ilan Hadar received additional equity compensation, aligning his incentives with the company's performance.
Key Dates
| Date | Description |
|---|---|
| August 15, 2024 | Power of Attorney granted by Ilan Hadar to Mirit Horenshtein Hadar. |
| November 29, 2024 | Effective date of 1-for-9 reverse share split by Silexion Therapeutics Corp. |
| July 29, 2025 | Effective date of 1-for-15 reverse share split by Silexion Therapeutics Corp. |
| February 20, 2026 | Date of transaction: grant of fully vested restricted share units to Ilan Hadar. |
| February 23, 2026 | Date Form 4 was signed by the attorney-in-fact. |
| March 24, 2032 | Expiration date of stock options held by Ilan Hadar. |
Recommendation
sellThe disclosure of two substantial reverse stock splits (1-for-9 and 1-for-15) within a short period strongly suggests severe financial distress and a significant erosion of shareholder value. While an insider share grant can be a positive signal of management alignment, the context of these reverse splits overshadows it, indicating a company struggling to maintain its share price and potentially its listing. This pattern typically points to ongoing challenges and a high-risk investment profile, warranting a 'sell' recommendation.
Keywords
Silexion Therapeutics, SLXN, Form 4, Insider Trading, Share Grant, CEO Compensation, Restricted Share Units, Reverse Stock Split, Beneficial Ownership, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.